Previous Close | 7.58 |
Open | 7.61 |
Bid | 8.01 x 4000 |
Ask | 8.06 x 1000 |
Day's Range | 7.58 - 8.07 |
52 Week Range | 6.21 - 20.16 |
Volume | 1,177,224 |
Avg. Volume | 1,544,021 |
Market Cap | 1.285B |
Beta (3Y Monthly) | 2.14 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.55 |
Earnings Date | Feb 27, 2019 - Mar 4, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 20.50 |
Oil made a slight recovery from Thursday morning's lows. Yahoo Finance's Julie Hyman, Adam Shapiro, and Dan Roberts discuss with Benchmark Investments' CEO Kevin Kelly.
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- First UltraCAR-T targeting solid tumors to enter the clinic - First-in-class therapy using autologous CAR-T cells targeting advanced ovarian cancer GERMANTOWN, Md. , Feb. 11, 2019 /PRNewswire/ -- Precigen, ...
Intrexon Corp NASDAQ/NGS:XONView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for XON with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting XON. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding XON totaled $7.07 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Merck KGaA (MKGAF) inks an exclusive licensing agreement with Vertex for two DNA-dependent protein kinase inhibitors in the field of gene editing for six specific genetic disease indications.
There's a new cannabis player that demands your attention.
Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.
Companies to apply Intrexon's proprietary Botticelli(TM) platform toward rapid and sustainable cannabis plantlet production Coalinga, California and Davis, California--(Newsfile Corp. - January 15, 2019) - Next Green Wave Holdings Inc. (CSE: NGW) (OTCQB: NXGWF) ("Next Green Wave") and Intrexon Corporation (NASDAQ: XON) ("Intrexon") are pleased to announce they have entered into a strategic licensing agreement to utilize Intrexon's Botticelli™ next generation plant propagation platform to enable rapid production of Next Green Wave's proprietary cannabis cultivars ...
DAVIS, Calif. and COALINGA, Calif., Jan. 15, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON) ("Intrexon"), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and Next Green Wave Holdings Inc. (NGW.CN) (NXGWF) ("Next Green Wave") are pleased to announce they have entered into a strategic licensing agreement to utilize Intrexon's Botticelli™ next generation plant propagation platform to enable rapid production of Next Green Wave's proprietary cannabis cultivars for the California market. The collaborative work conducted at Next Green Wave's facilities will also accelerate its vision of becoming a world-class nursery.
Companies to apply Intrexon's proprietary Botticelli(TM) platform toward rapid and sustainable cannabis plantlet production Coalinga, California and Davis, California--(Newsfile Corp. - January 15, 2019) - Next Green Wave Holdings Inc. (CSE: NGW) (OTCQB: NXGWF) ("Next Green Wave") and Intrexon Corporation (NASDAQ: XON) ("Intrexon") are pleased to announce they have entered into a strategic licensing agreement to utilize Intrexon's Botticelli™ next generation plant propagation platform to enable rapid production of Next Green Wave's proprietary cannabis cultivars for ...
Leading the way, NASDAQ’s first listed cannabis stock, Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) and Ginkgo Bioworks, the organism company, in early September announced a partnership to produce cultured cannabinoids.
GERMANTOWN, Md. , Jan. 2, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
Company to provide first-look at preclinical and clinical portfolio GERMANTOWN, Md. , Dec. 31, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a ...
- Executive leadership to discuss recent announcements GERMANTOWN, Md. , Dec. 24, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON), and a biopharmaceutical ...
- First CAR-T therapy to be administered within two days following non-viral gene transfer - First-in-class therapy for AML GERMANTOWN, Md. , Dec. 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned ...
SIOUX CENTER, Iowa, Dec. 21, 2018 /PRNewswire/ -- Exemplar Genetics, a subsidiary of Intrexon Corporation (XON) and market leader in the development of genetically engineered miniswine as models of human disease, and Mayo Clinic have launched a joint venture focused on the development of a high quality source of human liver cells or hepatocytes (HHCs). The new company, Cytotheryx, headquartered in Rochester, Minnesota, will leverage the expertise and experience of Exemplar Genetics with the capabilities of Mayo Clinic's researchers to deliver this much-needed resource. Human hepatocytes are necessary for drug toxicology studies, hepatitis virus research and gene therapy testing.
AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), is pleased to announce that the U.S. Department of Agriculture has released its disclosure standards for the labeling of products containing bioengineered components. The safety of these materials is assured by other regulatory processes, but the Bioengineered Food Disclosure Standard provides a national marketing standard to communicate the presence of these materials to consumers. Dr. Ronald Stotish, CEO, commented: “The issuance of these rules is a major step forward in providing a national standard for labeling foods and food materials in an objective and unbiased manner.
DARMSTADT, Germany , December 20, 2018 /PRNewswire/ -- Not intended for UK-based media Agreement enables Merck KGaA, Darmstadt, Germany , to maintain an investment in the rapidly advancing oncology field ...
- Merck KGaA, Darmstadt, Germany, to assign its Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon - Intrexon to issue Merck KGaA, Darmstadt, Germany, $150 million in Intrexon stock and a $25 ...
GERMANTOWN, Md. and MAYNARD, Mass., Dec. 18, 2018 /PRNewswire/ -- Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and AquaBounty Technologies, Inc. (AQB), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon, announced that their jointly developed gene edited line of tilapia, FLT 01, is exempt from GM regulation according to Argentina's National Advisory Commission on Agricultural Biotechnology (CONABIA). This line of tilapia enables more sustainable production through improvements in fillet yield, growth and feed conversion efficiency, enabling the tilapia to grow to market weight in less time, while also consuming less feed than conventional varieties.
Investors need to pay close attention to Intrexon (XON) stock based on the movements in the options market lately.
Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.